Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Molecular Oncology · 2026-11 · 20 (11) · 2820-2838
DOI: 10.1002/1878-0261.70271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 29.05.2026. Verfasst von Anne Schreuder und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Leiden University Medical Center, The Netherlands. Hauptthemen laut MEDLINE: BRCA1 Protein, Alleles. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Exacte en Natuurwetenschappen, Oncode Institute.
Abstract (Originalsprache)
With the recent rise in CRISPR/Cas9‐mediated genome‐wide synthetic lethality screens, many new synthetic lethal targets have been identified for diseases with underlying genetic causes such as tumours with BRCA1 mutations. Such screens often use full deficiency of a protein to identify novel vulnerabilities. However, patient‐derived mutations not only result in full loss of the protein but often also concern missense mutations with hypomorphic phenotypes. Here, we study the genetic vulnerabilities of two previously described hypomorphic BRCA1 missense mutations and compare these to a BRCA1‐depleted setting to study whether this affects screening for synthetic lethal interactions. Our research showed that BRCA1 I26A mutated cells have very similar vulnerabilities to BRCA1 wild‐type cells, confirming its low tumorigenic effect. In contrast, the BRCA1 R1699Q mutation induced a more similar phenotype to BRCA1‐deficient cells. For this mutation, we also unveiled a unique vulnerability to the loss of NDE1. Specifically in BRCA1 R1699Q mutated cells, and not BRCA1‐proficient or ‐deficient cells, NDE1 loss leads to increased genomic instability. Altogether, our findings highlight the importance to differentiate between patient‐derived mutations when assessing novel treatment targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, Leiden University Medical Center, The Netherlands.
- Oncode Institute, Utrecht, The Netherlands.
- Department of Clinical Genetics, Section Oncogenetics, Cancer Center Amsterdam, Amsterdam University Medical Center, The Netherlands.
- Laboratory of Applied Molecular Signalling, State University of Campinas, Brazil.
- Laboratory of Applied Molecular Signalling, Federal University of São Paulo, Brazil.
ORCID-Profile: Tiemen J Wendel, Sylvie M Noordermeer
Förderung
- Exacte en Natuurwetenschappen
- Oncode Institute
Zitieren
APA
Schreuder, A., de Lint, K., Mỹ Phúc Võ, H., Góis, M. M., Kampen, R. A., San Martin Alonso, M., Nootenboom, I., Garzero, V., Wendel, T. J., Wolthuis, R. M. F., & Noordermeer, S. M. (2026). Finding novel vulnerabilities of hypomorphic BRCA1 alleles. Molecular Oncology, 20(11), 2820-2838. https://doi.org/10.1002/1878-0261.70271
Vancouver
Schreuder A, de Lint K, Mỹ Phúc Võ H, Góis MM, Kampen RA, San Martin Alonso M, et al. Finding novel vulnerabilities of hypomorphic BRCA1 alleles. Molecular Oncology. 2026;20(11):2820-2838. doi:10.1002/1878-0261.70271
BibTeX
@article{Schreuder2026,
author = {Schreuder, Anne and de Lint, Klaas and Mỹ Phúc Võ, Hồ and Góis, Mariana M and Kampen, Rosalie A and San Martin Alonso, Marta and Nootenboom, Ilse and Garzero, Veronica and Wendel, Tiemen J and Wolthuis, Rob M F and Noordermeer, Sylvie M},
title = {Finding novel vulnerabilities of hypomorphic BRCA1 alleles},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {11},
pages = {2820--2838},
doi = {10.1002/1878-0261.70271}
}
EUVIMED